Annals of Oncology Advance Access published online on May 19, 2005
Annals of Oncology, doi:10.1093/annonc/mdi254
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Northwestern University Feinberg School of Medicine, Chicago, IL, USA
* To whom correspondence should be addressed. Background: To evaluate clinical and pathologic response to neoadjuvant docetaxel therapy in patients with stage III breast cancer. Patients and methods: Forty-five patients were planned to receive four cycles of docetaxel 100 mg/m2 every 3 weeks, followed by surgery, four cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (AC) every 3 weeks, radiation therapy (RT), and tamoxifen when indicated. Results: After four cycles of neoadjuvant docetaxel, the clinical response rate within the breast was 59% (95% CI 42% to 73%) and overall (breast and axilla) was 49% (95% CI 38% to 72%) in the intention-to-treat (ITT) population. At the time of surgery, 10% (n=4) of patients had a pathologic complete response (pCR) in the breast, 27% (n=11) had a pCR within the axillary lymph nodes, and 7% (n=3) had a pCR in the breast and axilla (95% CI 2% to 21%). An additional 5% (n=2) had minimal residual invasive tumor (<5 mm). The 5-year overall survival rate was 80%. The percentage of patients with grade 3/4 neutropenia was similar during docetaxel (93%) and AC (86%), while a greater percentage of patients had febrile neutropenia during docetaxel treatment (27%) compared with AC treatment (7%). Conclusions: Neoadjuvant docetaxel followed by surgery, adjuvant AC, hormonal therapy where indicated, and RT is an active regimen for patients with stage III breast cancer.
Received September 30, 2004
Revised March 4, 2005
Accepted April 15, 2005
Original article
Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer
,,
2 Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, DHHS Bethesda, MD, USA
3 University of Tennessee Cancer Institute, Memphis, TN, USA
4 Tufts New England Medical Center, Boston, MA, USA
5 Carolinas-Hematology Oncology Associates and the Blumenthal Cancer Center, Charlotte, NC, USA
6 Aventis Pharmaceuticals, Bridgewater, NJ, USA
S. M. Swain, E-mail: swains{at}mail.nih.gov
Abstract These authors contributed equally to this work.These authors contributed equally to this work.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. M. Sikov, D. S. Dizon, R. Strenger, R. D. Legare, K. P. Theall, T. A. Graves, J. S. Gass, T. A. Kennedy, and M. A. Fenton Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study J. Clin. Oncol., October 1, 2009; 27(28): 4693 - 4700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Baselga, M. Zambetti, A. Llombart-Cussac, G. Manikhas, E. Kubista, G. G. Steger, A. Makhson, S. Tjulandin, H. Ludwig, M. Verrill, et al. Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer J. Clin. Oncol., February 1, 2009; 27(4): 526 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Rivera, J. Lee, and A. Davies Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors Oncologist, December 1, 2008; 13(12): 1207 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Puhalla, E. Mrozek, D. Young, S. Ottman, A. McVey, K. Kendra, N. J. Merriman, M. Knapp, T. Patel, M. E. Thompson, et al. Randomized Phase II Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin Plus Cyclophosphamide in Axillary Node-Positive Breast Cancer J. Clin. Oncol., April 1, 2008; 26(10): 1691 - 1697. [Abstract] [Full Text] [PDF]
|
|